NCT02629523: LiquidLung-A

Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA

Completed Phase 2 Last updated 3 August 2021

What this trial tests

Phase 2 trial testing Afatinib in Lung Neoplasms in 21 participants. Completed in 11 May 2020.

Timeline

1 June 2016

Primary endpoint
31 December 2018

11 May 2020

Quick facts

Lead sponsor	Chonnam National University Hospital
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	21
Start date	1 June 2016
Primary completion	31 December 2018
Estimated completion	11 May 2020
Sites	1 location across South Korea

Drugs / interventions tested

• Afatinib (afatinib) — full drug profile →

Conditions studied

• Lung Neoplasms — all drugs for Lung Neoplasms →
• EGFR Gene Mutation — all drugs for EGFR Gene Mutation →

Sponsor

Chonnam National University Hospital

Who can join

19 and older, any sex, with Lung Neoplasms or EGFR Gene Mutation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Treatment efficacy of afatinib will be assessed in patients with lung cancer harboring EGFR mutations which were detected from circulating tumor DNA.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology.
   Bartolomucci A, Nobrega M, Ferrier T, Dickinson K, et al · · 2025 · cited 72× · PMID 40122951 · DOI 10.1038/s41698-025-00876-y
2. Phase II open-label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA: Liquid-Lung-A.
   Park CK, Lee SY, Lee JC, Choi CM, et al · · 2021 · cited 5× · PMID 33270375 · DOI 10.1111/1759-7714.13763